Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.55 +1.78 (+3.65%)

Streaming Delayed Price Updated: 11:38 AM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

After Copycat Boom, China's Drugmakers Target Global Generics ↗

September 03, 2025

Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.

Via Benzinga

Topics Supply Chain

Should You Buy Novo Nordisk Stock Now or Wait? ↗

September 03, 2025

NVO stock is down 60% over the past 12 months.

Via The Motley Fool

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 03, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 03, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

September 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Is Novo Nordisk Stock a Buy Now? ↗

September 03, 2025

A 57% risk reduction for heart attacks and strokes sounds like an amazing result.

Via The Motley Fool

Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades ↗

September 03, 2025

Rep. Marjorie Taylor Greene buys Google stock just days before a key antitrust ruling. See her latest trades and portfolio performance.

Via Benzinga

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report ↗

September 03, 2025

Via Stocktwits

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

September 02, 2025

From Pomerantz LLP

Via GlobeNewswire

NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

September 02, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 02, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 02, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death ↗

September 02, 2025

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

August 30, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

August 30, 2025

NOVO-NORDISK (NVO) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook ↗

August 29, 2025

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

August 29, 2025

From Pomerantz LLP

Via GlobeNewswire

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗

August 29, 2025

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

Via The Motley Fool

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

August 28, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda ↗

August 28, 2025

Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy.

Via Benzinga

Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗

August 28, 2025

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.

Via Benzinga

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

August 28, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today? ↗

August 28, 2025

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop...

Via Stocktwits

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk ↗

August 28, 2025

Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs.

Via Investor's Business Daily

NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

August 28, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

August 28, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure ↗

August 28, 2025

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.

Via Investor's Business Daily

UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears ↗

August 28, 2025

Patients in UK struggle to obtain Mounjaro drug due to high demand, sharp price increase. Shortages causing stress and health risks.

Via Benzinga

Stevens Capital Closes Out Position in Eli Lilly ↗

August 28, 2025

Via The Motley Fool

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today